Can a biologic tame COPD's repeated Flare-Ups?

NCT ID NCT04133909

Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Aug 21, 2026 · Last updated Aug 21, 2026

Summary

This trial tests whether mepolizumab, an injectable biologic, can reduce the number of moderate or severe flare-ups in people with chronic obstructive pulmonary disease (COPD) who have high levels of eosinophils (a type of white blood cell linked to inflammation). Participants receive either mepolizumab or a placebo every four weeks, added to their usual COPD medications, for at least a year. The study aims to see if this approach can help control the disease and improve quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: mepolizumab (an injectable biologic) given as an add-on to standard COPD therapy
What this could lead to: If successful, mepolizumab could become a new add-on treatment to reduce the frequency of COPD flare-ups in patients with elevated eosinophil levels.
What could go wrong: This is a Phase 3 trial, but results may not confirm benefit in all patients. Possible risks include injection site reactions and allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

806 people

The number who actually took part.

Started

Oct 2019

Finished

Aug 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participant must be at least 40 years of age at Screening Visit 1. * Participants with a peripheral blood eosinophil count of \>=300 cells per microliter (μL) from the hematology sample collected at Screening Visit 0 AND a documented historical blood eosinophil count of \>=150 cells per μL in the 12 months prior to Screening Visit 0 that meets the following: It must have been measured between 12 months and 1 month prior to Screening Visit 0, and it must not have been measured within 14 days of a COPD exacerbation. Participants with no documented historical blood eosinophil count of \>=150 cells per µL must meet this threshold at the Screening Visit 1 assessment. * Participants with a clinically documented history of COPD for at least 1 year in accordance with the definition by the American Thoracic Society or European Respiratory Society. * Participants must present with a measured pre- and post-salbutamol Forced expiratory volume in one second (FEV1)/Forced vital capacity (FVC) ratio of \<0.70 at Screening Visit 1 to confirm the diagnosis of COPD and with a measured post-salbutamol FEV1\>20% and \<=80% of predicted normal values calculated using NHANES III reference equations at Screening Visit 1. * Participants must have a well-documented history (for example, medical record verification) in the 12 months prior to Screening Visit 1 of two or more moderate COPD exacerbations that were treated with systemic corticosteroids (intramuscular \[IM\], intravenous, or oral) with or without antibiotics or at least one severe COPD exacerbation requiring hospitalization. * Participants must have a well-documented requirement for optimized standard of care background therapy that includes inhaled corticosteroids (ICS) plus 2 additional COPD medications (ICS-based triple therapy) for the 12 months prior to Screening Visit 1 and meets the following criteria: immediately prior to Screening Visit 1, minimum of 3 months of use of an 1) inhaled corticosteroid at a dose \>=500 microgram (mcg) per day fluticasone propionate dose equivalent plus 2) Long acting beta2-agonist (LABA) and 3) Long acting muscarinic antagonist (LAMA) unless documentation of safety or intolerance issues related to LABA or LAMA. For participants who are not continually maintained on ICS plus LABA plus LAMA for the entire 12 months prior to Visit 1 use of the following is allowed (but not in the 3 months immediately prior to Visit 1); inhaled corticosteroid at a dose \>=500 mcg per day fluticasone propionate dose equivalent plus inhaled LABA or inhaled LAMA and Phosphodiesterase-4-inhibitors, methylxanthines, or scheduled daily use of short acting beta2-agonist (SABA) and/or short acting muscarinic antagonist (SAMA). * Current or former cigarette smokers with a history of cigarette smoking of \>=10 pack-years at Screening (Visit 1) calculated as (number of pack years = \[number of cigarettes per day/20\] multiplied by number of years smoked \[For example, 20 cigarettes per day for 10 years or 10 cigarettes per day for 20 years\]). * Contraceptive use for female participant should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. * A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies: She is not a woman of childbearing potential (WOCBP) or she is a WOCBP and using a contraceptive method that is highly effective, with a failure rate of \<1%, during the intervention period and for at least 16 weeks after the last dose of study intervention. The principal investigator (PI) should evaluate the effectiveness of the contraceptive method in relation to the first dose of study intervention. * A WOCBP must have a negative highly sensitive pregnancy urine test within 24 hours before the first dose of study intervention. If a urine test cannot be confirmed as negative (For example, an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive. * Participants capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. * Participants must meet following randomization inclusion criteria at Visit 2 to be randomized and commence the study intervention period: a) Participants that do not have documented historical blood eosinophil count of ≥150 cells/μL prior to Screening Visit must meet this threshold based on the Screening Visit 1 assessment, b) Participants must have eosinophil count of ≥300 cells/μL from the hematology sample collected at Screening Visit 0, c) Compliance with completion of the e-diary defined as completion of all questions on 5 or more days out of the 7 days immediately preceding Visit 2. Exclusion Criteria: * Participants with a past history or concurrent diagnosis of asthma are excluded regardless of whether they have active or inactive disease. * The Investigator must judge that COPD is the primary diagnosis accounting for the clinical manifestations of the lung disease. Participants with alpha1-antitrypsin deficiency as the underlying cause of COPD are excluded. Also, excluded are participants with active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, primary pulmonary hypertension, interstitial lung diseases or other active pulmonary diseases. * Participants with pneumonia, COPD exacerbation, or lower respiratory tract infection within the 4 weeks prior to Screening Visit 1. * Participants with lung volume reduction surgery within the 12 months prior to Screening Visit 1. * Participation in the acute phase of a pulmonary rehabilitation program within 4 weeks prior to Screening Visit 1. Participants who are in the maintenance phase of a pulmonary rehabilitation program are not excluded. * Participants receiving treatment with oxygen more than 2 liter (L) per minute at rest over 24 hours. For participants receiving oxygen treatment, participants should demonstrate an oxyhemoglobin saturation greater than or equal to 89% while breathing supplemental oxygen. * Participants with a QT interval, from the electrocardiogram (ECG) conducted at Screening Visit 1, corrected with Fridericia's formula (QTcF) \>450 millisecond (msec) (or QTcF \>480 msec in participants with bundle branch block). Fridericia's formula must be used to determine eligibility and discontinuation for an individual participant. Participants are excluded if an abnormal ECG finding from the 12-lead ECG conducted at Screening Visit 1 is considered to be clinically significant and would impact the participant's participation during the study, based on the evaluation of the Investigator. * Participants with any of the following would be excluded: myocardial infarction or unstable angina in the 6 months prior to Screening Visit 1; unstable or life threatening cardiac arrhythmia requiring intervention in the 3 months prior to Screening Visit 1; New York Heart Association (NYHA) Class IV Heart failure. * Participants with (historical or) current evidence of clinically significant, neurological, psychiatric, renal, hepatic, immunological, endocrine (including uncontrolled diabetes or thyroid disease) or hematological abnormalities that are uncontrolled. Significant is defined as any disease that, in the opinion of the Investigator, would put the safety of the participant at risk through participation, or which could affect the efficacy or safety analysis if the disease/condition exacerbated during the study. * Participants with other conditions that could lead to elevated eosinophils such as Hypereosinophilic syndromes including Eosinophilic Granulomatosis with Polyangiitis (EGPA), also known as Churg-Strauss Syndrome, or Eosinophilic Esophagitis. * Participants with a known, pre-existing parasitic infestation within 6 months prior to Screening Visit 1. * A current malignancy or previous history of cancer in remission for less than 12 months prior to Screening Visit 1 (participants that had localized carcinoma of the skin or cervix which was resected for cure will not be excluded). * Participants with a known immunodeficiency (For example, human immunodeficiency virus \[HIV\]), other than that explained by the use of corticosteroids taken for COPD. * Participants with cirrhosis or current unstable liver disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice. Stable non-cirrhotic chronic liver disease (including Gilbert's syndrome, asymptomatic gallstones, and chronic stable hepatitis B or C -e.g., presence of hepatitis B surface antigen \[HbsAg\] or positive hepatitis C antibody test result) is acceptable if the participant otherwise meets entry criteria. * Participants who have received interventional product in previous mepolizumab studies are excluded. * Participants who have received any monoclonal antibody within 5 half-lives of Screening Visit 1. * Participants who have received an investigational drug within 30 days of Visit 1, or within 5 drug half-lives of the investigational drug, whichever is longer (this also includes investigational formulations of a marketed product). * Participants who have received short term use of oral corticosteroids within 30 days of Visit 1. * Participants with a known allergy or sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the Investigator or Medical Monitor, contraindicates participation in the study or intolerance to another monoclonal antibody or biologic including history of anaphylaxis to another biologic. * Participants at risk of non-compliance, or unable to comply with the study procedures. Any infirmity, disability, or geographic location that would limit compliance for scheduled visits. * Participants with conditions that will limit the validity of informed consent to participate in the study, for example, uncontrolled psychiatric disease or intellectual deficiency. * Participants with a known or suspected history of alcohol or drug abuse within 2 years prior to Visit 1. * Participant is an Investigator, sub-Investigator, study coordinator, employee of a participating Investigator or study site, or immediate family member of the aforementioned that is involved in this study. * Participants with a current active COVID-19 infection, either laboratory confirmed or according to the investigator's medical judgement and who are known to be in contact with active COVID-19 positive individuals within the past 14 days. * Participant will not be randomized if they meet any of the following randomization exclusion criteria at Visit 2: a) Participants who have pneumonia, exacerbation, lower respiratory infection during the Run-in period. b) Evidence of clinically significant abnormality in the hematological or biochemical screen at Visit 1, as judged by the Investigator. c) Participants who meet the following based on results from sample taken at Screening Visit 1: Alanine aminotransferase (ALT) \>2x upper limit of normal (ULN), bilirubin \>1.5 x ULN (isolated bilirubin \>1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%), cirrhosis or current unstable liver or biliary disease per Investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminaemia, oesophageal or gastric varices, or persistent jaundice. d) Participants who are pregnant or breastfeeding. Participants should not be randomized if they plan to become pregnant during the time of study participation. e) Participants that had an active COVID-19 infection during the Run-in period, either laboratory confirmed or according to the investigator's medical judgment or known to be in contact with active COVID-19 positive individuals within the past 14 days. f) Participants with a QT interval, from the ECG conducted at Visit 2, corrected with Fridericia's formula (QTcF) \>450 msec (or QTcF \>480 msec in participants with bundle branch block).

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease COPD, severe early onset

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pulmonary disease, chronic obstructive

Contacts and locations

Locations

GSK Investigational Site

Birmingham, Alabama, 35211, United States
GSK Investigational Site

Dothan, Alabama, 36305, United States
GSK Investigational Site

Huntsville, Alabama, 77340, United States
GSK Investigational Site

Jasper, Alabama, 35501, United States
GSK Investigational Site

Chandler, Arizona, 29720-1709, United States
GSK Investigational Site

Chandler, Arizona, 85224, United States
GSK Investigational Site

Gilbert, Arizona, 85296, United States
GSK Investigational Site

Mesa, Arizona, 85206, United States
GSK Investigational Site

Phoenix, Arizona, 85020, United States
GSK Investigational Site

Phoenix, Arizona, 85050, United States
GSK Investigational Site

Phoenix, Arizona, 89014, United States
GSK Investigational Site

Tucson, Arizona, 85741, United States
GSK Investigational Site

Conway, Arkansas, 72032, United States
GSK Investigational Site

Alpine, California, 92262, United States
GSK Investigational Site

Cerritos, California, 90703, United States
GSK Investigational Site

Newport Beach, California, 92663, United States
GSK Investigational Site

San Diego, California, 92120, United States
GSK Investigational Site

Torrance, California, 90503-4818, United States
GSK Investigational Site

Vista, California, 92083, United States
GSK Investigational Site

Colorado Springs, Colorado, 80907, United States
GSK Investigational Site

Boynton Beach, Florida, 33472-2952, United States
GSK Investigational Site

Clearwater, Florida, 33765, United States
GSK Investigational Site

Daytona Beach, Florida, 32117, United States
GSK Investigational Site

Doral, Florida, 33172-1604, United States
GSK Investigational Site

Hialeah, Florida, 33016, United States
GSK Investigational Site

Homestead, Florida, 33032, United States
GSK Investigational Site

Miami, Florida, 33126, United States
GSK Investigational Site

Miami, Florida, 33144-257, United States
GSK Investigational Site

Miami, Florida, 33144, United States
GSK Investigational Site

Miami, Florida, 33155, United States
GSK Investigational Site

Miami, Florida, 33173-3259, United States
GSK Investigational Site

Miami, Florida, 33174, United States
GSK Investigational Site

Miami, Florida, 33186-6597, United States
GSK Investigational Site

Miami Lakes, Florida, 33014-2473, United States
GSK Investigational Site

Miami Lakes, Florida, 33016, United States
GSK Investigational Site

Orlando, Florida, 32825, United States
GSK Investigational Site

Pinellas Park, Florida, 33781, United States
GSK Investigational Site

Plantation, Florida, 33324, United States
GSK Investigational Site

Port Orange, Florida, 32127, United States
GSK Investigational Site

St. Petersburg, Florida, 33704, United States
GSK Investigational Site

Adairsville, Georgia, 30103, United States
GSK Investigational Site

Johns Creek, Georgia, 30022-7484, United States
GSK Investigational Site

Lawrenceville, Georgia, 30046, United States
GSK Investigational Site

Woodstock, Georgia, 30189, United States
GSK Investigational Site

Chicago, Illinois, 60602, United States
GSK Investigational Site

Evansville, Indiana, 47714, United States
GSK Investigational Site

Valparaiso, Indiana, 46383, United States
GSK Investigational Site

Lexington, Kentucky, 40503, United States
GSK Investigational Site

Baltimore, Maryland, 21224-2141, United States
GSK Investigational Site

Columbia, Maryland, 21044, United States
GSK Investigational Site

Lathrup Village, Michigan, 48076, United States
GSK Investigational Site

St Louis, Missouri, 63141, United States
GSK Investigational Site

Las Vegas, Nevada, 89106, United States
GSK Investigational Site

Toms River, New Jersey, 08755, United States
GSK Investigational Site

The Bronx, New York, 10455, United States
GSK Investigational Site

Charlotte, North Carolina, 28054, United States
GSK Investigational Site

Gastonia, North Carolina, 28054, United States
GSK Investigational Site

Greenville, North Carolina, 29340, United States
GSK Investigational Site

Hickory, North Carolina, 28601, United States
GSK Investigational Site

Shelby, North Carolina, 28150, United States
GSK Investigational Site

Wilmington, North Carolina, 28401, United States
GSK Investigational Site

Winston-Salem, North Carolina, 27103, United States
GSK Investigational Site

Cincinnati, Ohio, 45236, United States
GSK Investigational Site

Columbus, Ohio, 43016, United States
GSK Investigational Site

Columbus, Ohio, 43215, United States
GSK Investigational Site

Kettering, Ohio, 45439-2201, United States
GSK Investigational Site

Norman, Oklahoma, 73072, United States
GSK Investigational Site

Oklahoma City, Oklahoma, 73111, United States
GSK Investigational Site

Oregon City, Oregon, 97220, United States
GSK Investigational Site

Altoona, Pennsylvania, 15801, United States
GSK Investigational Site

Philadelphia, Pennsylvania, 19140, United States
GSK Investigational Site

Anderson, South Carolina, 29621, United States
GSK Investigational Site

Charleston, South Carolina, 29406-7108, United States
GSK Investigational Site

Clinton, South Carolina, 29325, United States
GSK Investigational Site

Fort Mill, South Carolina, 29707, United States
GSK Investigational Site

Greenville, South Carolina, 29615, United States
GSK Investigational Site

Rock Hill, South Carolina, 29732, United States
GSK Investigational Site

Spartanburg, South Carolina, 29303, United States
GSK Investigational Site

Knoxville, Tennessee, 37909, United States
GSK Investigational Site

Corsicana, Texas, 75110, United States
GSK Investigational Site

Houston, Texas, 77042-4643, United States
GSK Investigational Site

Houston, Texas, 77479, United States
GSK Investigational Site

McKinney, Texas, 75069, United States
GSK Investigational Site

San Antonio, Texas, 78229, United States
GSK Investigational Site

San Antonio, Texas, 78258, United States
GSK Investigational Site

Sherman, Texas, 75092, United States
GSK Investigational Site

Webster, Texas, 77598, United States
GSK Investigational Site

Rutland, Vermont, 05701, United States
GSK Investigational Site

Berazategui Buenos Aires, B1884AAC, Argentina
GSK Investigational Site

Buenos Aires, 1646, Argentina
GSK Investigational Site

Buenos Aires, C1426ABP, Argentina
GSK Investigational Site

Ciudad AutOnoma de Buenos Aire, C1425AZE, Argentina
GSK Investigational Site

Ciudad Autonoma de Bueno, C1122AAK, Argentina
GSK Investigational Site

Ciudad Autonoma de Bueno, C1414AIF, Argentina
GSK Investigational Site

Córdoba, X5003DCE, Argentina
GSK Investigational Site

La Plata, B1902COS, Argentina
GSK Investigational Site

Lobos, 7240, Argentina
GSK Investigational Site

Mar del Plata, 7600, Argentina
GSK Investigational Site

Mar del Plata, B7600DHK, Argentina
GSK Investigational Site

Mendoza, 5500, Argentina
GSK Investigational Site

Mendoza, M5500CCG, Argentina
GSK Investigational Site

Quilmes, B1878FNR, Argentina
GSK Investigational Site

Rosario, 2000, Argentina
GSK Investigational Site

Rosario, S2002OJN, Argentina
GSK Investigational Site

Rosario Provincia de Santa FE, C1121ABE, Argentina
GSK Investigational Site

San Miguel de Tucumán, 4000, Argentina
GSK Investigational Site

San Miguel de Tucumán, T4000IHE, Argentina
GSK Investigational Site

San Rafael, 5600, Argentina
GSK Investigational Site

Coffs Harbour, New South Wales, 2450, Australia
GSK Investigational Site

New Lambton, New South Wales, 2305, Australia
GSK Investigational Site

Sydney, New South Wales, 2010, Australia
GSK Investigational Site

Kent Town, South Australia, 5067, Australia
GSK Investigational Site

Frankston, Victoria, 3199, Australia
GSK Investigational Site

Jambes, 5100, Belgium
GSK Investigational Site

Liège, 4000, Belgium
GSK Investigational Site

Yvoir, 5530, Belgium
GSK Investigational Site

Porto Alegre, 90035-074, Brazil
GSK Investigational Site

Porto Alegre, 90430-000, Brazil
GSK Investigational Site

Porto Alegre, 90610000, Brazil
GSK Investigational Site

São Paulo, 05403-000, Brazil
GSK Investigational Site

Vancouver, British Columbia, V5Z 4E1, Canada
GSK Investigational Site

Truro, Nova Scotia, B2N 1L2, Canada
GSK Investigational Site

Ajax, Ontario, L1S 2J5, Canada
GSK Investigational Site

Sarnia, Ontario, N7T 4X3, Canada
GSK Investigational Site

Windsor, Ontario, N8X 1T3, Canada
GSK Investigational Site

Saint-Charles-Borromée, Quebec, J6E 2B4, Canada
GSK Investigational Site

Baotou, 014010, China
GSK Investigational Site

Beijing, 100020, China
GSK Investigational Site

Beijing, 100034, China
GSK Investigational Site

Beijing, 100730, China
GSK Investigational Site

Changchun, 130021, China
GSK Investigational Site

Changchun, 130041, China
GSK Investigational Site

Changsha, 410004, China
GSK Investigational Site

Changsha, 410005, China
GSK Investigational Site

Changsha, 410008, China
GSK Investigational Site

Changsha, 410013, China
GSK Investigational Site

Guangzhou, 510080, China
GSK Investigational Site

Guangzhou, 510150, China
GSK Investigational Site

Guangzhou, 51080, China
GSK Investigational Site

Haikou, 570311, China
GSK Investigational Site

Hangzhou, 310006, China
GSK Investigational Site

Hangzhou, 310009, China
GSK Investigational Site

Hohehot, 010050, China
GSK Investigational Site

Jiaxing, 314001, China
GSK Investigational Site

Jinan, 250013, China
GSK Investigational Site

Nanchang, 330006, China
GSK Investigational Site

Nanchang, 330038, China
GSK Investigational Site

Nanchang, 330200, China
GSK Investigational Site

Nanjing, 210009, China
GSK Investigational Site

Nanjing, 210029, China
GSK Investigational Site

Nanning, 530021, China
GSK Investigational Site

Qingdao, 266071, China
GSK Investigational Site

Shanghai, 200032, China
GSK Investigational Site

Shanghai, 200040, China
GSK Investigational Site

Shanghai, 200120, China
GSK Investigational Site

Shanghai, 201100, China
GSK Investigational Site

Taiyuan, 30000, China
GSK Investigational Site

Taizhou, 318000, China
GSK Investigational Site

Ürümqi, 830054, China
GSK Investigational Site

Wuhan, 430024, China
GSK Investigational Site

Wuxi, 214023, China
GSK Investigational Site

Xiamen, 361004, China
GSK Investigational Site

Xining, 810007, China
GSK Investigational Site

Xinxiang, 453000, China
GSK Investigational Site

Zhuhai, 519001, China
GSK Investigational Site

Zigong, 643036, China
GSK Investigational Site

Aalborg, 9100, Denmark
GSK Investigational Site

Hvidovre, DK-2650, Denmark
GSK Investigational Site

Kbenhavn N, 2100, Denmark
GSK Investigational Site

Koebenhavn NV, 2400, Denmark
GSK Investigational Site

Odense C, DK-5000, Denmark
GSK Investigational Site

Roskilde, 4000, Denmark
GSK Investigational Site

Vejle, 7100, Denmark
GSK Investigational Site

Tallinn, 50-088, Estonia
GSK Investigational Site

Brest, 29609, France
GSK Investigational Site

Cholet, 49300, France
GSK Investigational Site

Epagny Metz-Tessy, 74374, France
GSK Investigational Site

Le Mans, 72000, France
GSK Investigational Site

Lyon, 69004, France
GSK Investigational Site

Montpellier, 34295, France
GSK Investigational Site

Mulhouse, 68100, France
GSK Investigational Site

Berlin, 10119, Germany
GSK Investigational Site

Berlin, 10367, Germany
GSK Investigational Site

Berlin, 10717, Germany
GSK Investigational Site

Berlin, 10787, Germany
GSK Investigational Site

Berlin, 12157, Germany
GSK Investigational Site

Berlin, 12203, Germany
GSK Investigational Site

Berlin, 12627, Germany
GSK Investigational Site

Cottbus, 03050, Germany
GSK Investigational Site

Frankfurt, 60313, Germany
GSK Investigational Site

Frankfurt, 60389, Germany
GSK Investigational Site

Frankfurt, 60596, Germany
GSK Investigational Site

Geesthacht, 21502, Germany
GSK Investigational Site

Gelsenkirchen, 45879, Germany
GSK Investigational Site

Halle, 06108, Germany
GSK Investigational Site

Immenhausen, 34376, Germany
GSK Investigational Site

Koblenz, 56068, Germany
GSK Investigational Site

Leipzig, 04103, Germany
GSK Investigational Site

Leipzig, 04207, Germany
GSK Investigational Site

Leipzig, 04275, Germany
GSK Investigational Site

Leipzig, 04357, Germany
GSK Investigational Site

Lübeck, 23552, Germany
GSK Investigational Site

Mainz, 55131, Germany
GSK Investigational Site

Neu-Isenburg, 63263, Germany
GSK Investigational Site

Peine, 31224, Germany
GSK Investigational Site

Rheine, 48431, Germany
GSK Investigational Site

Rodgau, 63110, Germany
GSK Investigational Site

Schleswig, 24837, Germany
GSK Investigational Site

Stuttgart, 70378, Germany
GSK Investigational Site

Alexandroupoli, 68100, Greece
GSK Investigational Site

Athens, 106 76, Greece
GSK Investigational Site

Athens, 11527, Greece
GSK Investigational Site

Ioannina, 455 00, Greece
GSK Investigational Site

Rio Patras, 26054, Greece
GSK Investigational Site

Thessaloniki, 57010, Greece
GSK Investigational Site

Budapest, 1036, Hungary
GSK Investigational Site

Budapest, 1125, Hungary
GSK Investigational Site

Debrecen, 4025, Hungary
GSK Investigational Site

Debrecen, 4032, Hungary
GSK Investigational Site

Gyula, 5700, Hungary
GSK Investigational Site

Hajdúnánás, 4080, Hungary
GSK Investigational Site

Hatvan, 3000, Hungary
GSK Investigational Site

Pécs, 7635, Hungary
GSK Investigational Site

Siófok, 8600, Hungary
GSK Investigational Site

Törökbálint, 2045, Hungary
GSK Investigational Site

Zalaegerszeg, 8900, Hungary
GSK Investigational Site

Ahmedabad, 380052, India
GSK Investigational Site

Hyderabad, 500003, India
GSK Investigational Site

Hyderabad, 500018, India
GSK Investigational Site

Jaipur, 302023, India
GSK Investigational Site

Kanpur, 208001, India
GSK Investigational Site

Lucknow, 226003, India
GSK Investigational Site

Nagpur, 440012, India
GSK Investigational Site

Nagpur, 44009, India
GSK Investigational Site

New Delhi, 110060, India
GSK Investigational Site

Drogheda, A92 VW28, Ireland
GSK Investigational Site

Dublin, D15 X40D, Ireland
GSK Investigational Site

Dublin, DO4T6F4, Ireland
GSK Investigational Site

Galway, H53 T971, Ireland
GSK Investigational Site

Limerick, V94 F858, Ireland
GSK Investigational Site

Ashkelon, 78278, Israel
GSK Investigational Site

Beer-Yaakov, 703000, Israel
GSK Investigational Site

Haifa, 34362, Israel
GSK Investigational Site

Holon, 58100, Israel
GSK Investigational Site

Jerusalem, 91031, Israel
GSK Investigational Site

Jerusalem, 91120, Israel
GSK Investigational Site

Kfar Saba, 44281, Israel
GSK Investigational Site

Petah Tikva, 49100, Israel
GSK Investigational Site

Ramat Gan, 52621, Israel
GSK Investigational Site

Rehovot, 76100, Israel
GSK Investigational Site

Bari, 70020, Italy
GSK Investigational Site

Ferrara, 44123, Italy
GSK Investigational Site

Roma, 00128, Italy
GSK Investigational Site

Telese Terme BN, 82037, Italy
GSK Investigational Site

Verona, 37134, Italy
GSK Investigational Site

Guadalajara, 44100, Mexico
GSK Investigational Site

Guadalajara, 44160, Mexico
GSK Investigational Site

Jalisco, 44130, Mexico
GSK Investigational Site

Monterrey, 64020, Mexico
GSK Investigational Site

Monterrey, 64460, Mexico
GSK Investigational Site

Breda, 4818 CK, Netherlands
GSK Investigational Site

Groningen, 9728 NT, Netherlands
GSK Investigational Site

Heerlen, 6419 PC, Netherlands
GSK Investigational Site

Rotterdam, 3045 PM, Netherlands
GSK Investigational Site

The Hague, 2545 AA, Netherlands
GSK Investigational Site

Zutphen, 7207 AE, Netherlands
GSK Investigational Site

Havelock North, Hawke's Bay Region, 3410, New Zealand
GSK Investigational Site

Auckland, 1051, New Zealand
GSK Investigational Site

Hamilton, 3240, New Zealand
GSK Investigational Site

Rotorua, 3010, New Zealand
GSK Investigational Site

Wellington, 6021, New Zealand
GSK Investigational Site

Bialystok, 15-044, Poland
GSK Investigational Site

Bydgoszcz, 85-796, Poland
GSK Investigational Site

Częstochowa, 42202, Poland
GSK Investigational Site

Elblag, 82-300, Poland
GSK Investigational Site

Gdansk, 80-382, Poland
GSK Investigational Site

Gdynia, 81-537, Poland
GSK Investigational Site

Katowice, 40-040, Poland
GSK Investigational Site

Katowice, 40-081, Poland
GSK Investigational Site

Kielce, 25-751, Poland
GSK Investigational Site

Krakow, 30-033, Poland
GSK Investigational Site

Krakow, 31-209, Poland
GSK Investigational Site

Lodz, 90-127, Poland
GSK Investigational Site

Lodz, 90-141, Poland
GSK Investigational Site

Ostrowiec Świętokrzyski, 27-400, Poland
GSK Investigational Site

Poznan, 60-214, Poland
GSK Investigational Site

Poznan, 60-702, Poland
GSK Investigational Site

Rzeszów, 35-051, Poland
GSK Investigational Site

Rzeszów, 35-205, Poland
GSK Investigational Site

Sopot, 81-741, Poland
GSK Investigational Site

Sosnowiec, 41-200, Poland
GSK Investigational Site

Warsaw, 01-192, Poland
GSK Investigational Site

Warsaw, 02-777, Poland
GSK Investigational Site

Wroclaw, 53-301, Poland
GSK Investigational Site

Zamość, 22-400, Poland
GSK Investigational Site

Daegu, 42415, South Korea
GSK Investigational Site

Incheon, 21431, South Korea
GSK Investigational Site

Incheon, 21565, South Korea
GSK Investigational Site

Jeonju, 54907, South Korea
GSK Investigational Site

Seoul, 02447, South Korea
GSK Investigational Site

Seoul, 02559, South Korea
GSK Investigational Site

Seoul, 02841, South Korea
GSK Investigational Site

Seoul, 06591, South Korea
GSK Investigational Site

Seoul, 143-729, South Korea
GSK Investigational Site

Alzira, 46600, Spain
GSK Investigational Site

Barcelona, 08003, Spain
GSK Investigational Site

Barcelona, 08017, Spain
GSK Investigational Site

Barcelona, 08036, Spain
GSK Investigational Site

Barcelona, 08907, Spain
GSK Investigational Site

Benalmádena, 29630, Spain
GSK Investigational Site

Cadiz, 10009, Spain
GSK Investigational Site

Cáceres, 10003, Spain
GSK Investigational Site

Galdakano, 48960, Spain
GSK Investigational Site

Granada, 18014, Spain
GSK Investigational Site

Granada, 18300, Spain
GSK Investigational Site

HebrOn, 08035, Spain
GSK Investigational Site

Madrid, 28007, Spain
GSK Investigational Site

Marbella, 29603, Spain
GSK Investigational Site

Pozuelo de AlarcOn Madr, 28223, Spain
GSK Investigational Site

Santiago de Compostela, 15706, Spain
GSK Investigational Site

Valencia, 46520, Spain
GSK Investigational Site

Zaragoza, 50009, Spain
GSK Investigational Site

Härnösand, SE-871 31, Sweden
GSK Investigational Site

Malmö, SE-211 52, Sweden
GSK Investigational Site

Uppsala, SE-752 37, Sweden
GSK Investigational Site

Taichung, 40705, Taiwan
GSK Investigational Site

Taipei, 11490, Taiwan
GSK Investigational Site

Birmingham, B15 2SQ, United Kingdom
GSK Investigational Site

Cardiff, CF159SS, United Kingdom
GSK Investigational Site

Glasgow, G20 0SP, United Kingdom
GSK Investigational Site

Hardwick, TS19 8PE, United Kingdom
GSK Investigational Site

Hexham, NE46 1QJ, United Kingdom
GSK Investigational Site

Lancashire, PR7 7NA, United Kingdom
GSK Investigational Site

Liverpool, CF15 9SS, United Kingdom
GSK Investigational Site

London, W1G 8HU, United Kingdom
GSK Investigational Site

Manchester, M15 6SE, United Kingdom
GSK Investigational Site

Norwich, NR4 7UY, United Kingdom
GSK Investigational Site

Reading, B15 2SQ, United Kingdom
GSK Investigational Site

Wishaw, ML2 0DP, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.